Quantcast

Latest Depomed Inc. Stories

2014-07-17 16:26:16

Opinion Expected "In Short Order" NEWARK, Calif., July 17, 2014 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today announced that on July 17, 2014, Judge Joel A. Pisano of the United States District Court for the District of New Jersey entered an order preliminarily enjoining Actavis Elizabeth LLC and Actavis Inc. from marketing a generic version of Gralise® (gabapentin) prior to the Court's issuance of an opinion in the matter. The order indicates the Court expects to issue an...

2014-07-16 08:27:57

NEWARK, Calif., July 16, 2014 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today announced the appointment of Srinivas G. Rao, MD, PhD, as Chief Medical Officer and Senior Vice President. Dr. Rao has extensive experience and background in pain and central nervous system diseases. He was the Founder and Chief Executive Officer of Kyalin Biosciences, a privately held biotechnology company developing a potential breakthrough therapy for autism, from its formation in 2011 through to its...

2014-06-18 08:28:42

NEWARK, Calif., June 18, 2014 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the JMP Securities 2014 Healthcare Conference in New York City. The presentation at the JMP conference is scheduled for 11:30 am ET (8:30 am PT) on Tuesday June 24, 2014. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be archived for 30...

2014-06-10 08:30:40

NEWARK, Calif., June 10, 2014 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the Wells Fargo 2014 Healthcare Conference in Boston. The presentation at the Wells Fargo conference is scheduled for 3:35 pm ET (12:35 pm PT) on Wednesday June 18, 2014. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be archived for 30...

2014-05-28 08:32:01

Controlled Substance Analgesic Combination Product Uses Depomed's Proprietary Acuform® Technology NEWARK, Calif., May 28, 2014 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) announced today that the U. S. Food and Drug Administration (FDA) has accepted for filing a New Drug Application (NDA) from Mallinckrodt (NYSE: MNK) for MNK-155. MNK-155 is an investigational extended-release oral formulation of hydrocodone and acetaminophen that has been studied for the management of moderate to...

2014-05-27 16:25:31

NEWARK, Calif., May 27, 2014 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it will be presenting at the Jefferies 2014 Global Healthcare Conference in New York City. The presentation at the Jefferies conference is scheduled for 11:00 am ET (8:00 am PT) on Tuesday June 3, 2014. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be archived for...

2014-05-09 16:24:36

NEWARK, Calif., May 9, 2014 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at two upcoming investor conferences: Bank of America Merrill Lynch Healthcare Conference in Las Vegas Nevada on Thursday May 15 at 11:00 am Eastern Time (8:00 am Pacific Time). UBS Global Healthcare Conference in New York City on Monday May 19 at 9:00 am Eastern Time (6:00 am Pacific Time). The presentations will be webcast, and the webcasts can be accessed via the...

2014-05-08 16:26:41

Conference call scheduled for today at 5:00 p.m. EDT NEWARK, Calif., May 8, 2014 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO), today reported financial results for the first quarter ended March 31, 2014. First Quarter 2014 Business Highlights -- Relaunched migraine product CAMBIA(®) (diclofenac potassium for oral solution) in February 2014 -- Achieved settlements with two of the three defendants in the Gralise(®) (gabapentin) patent litigation in April 2014...

2014-04-30 16:30:40

NEWARK, Calif., April 30, 2014 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release first quarter fiscal year 2014 financial results after the market closes on Thursday, May 8, 2014. The Company will host a conference call beginning at 5:00 pm Eastern time, 2:00 pm Pacific time to discuss its results. Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international). The conference call will also be available via a...

2014-04-14 12:33:34

NEWARK, Calif., April 14, 2014 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today announced it has entered into settlement agreements with two of the three defendants involved in Depomed's ongoing patent infringement litigation against filers of Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of Depomed's Gralise(®) (gabapentin) 300 mg and 600 mg tablets. The settlements permit the defendants to begin selling generic versions of Gralise on...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related